Fabio A.B. Schutz - Dana-Farber Cancer Institute, Boston, MA

基本信息

浏览量：73

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 85 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Aristotelis Bamias,Ian D Davis,Matthew D Galsky,José Á Arranz,Eiji Kikuchi,Enrique Grande,Xavier Garcia del Muro,Se Hoon Park,Ugo De Giorgi,Boris Alekseev,Marina Mencinger,Kouji Izumi,

The Lancet. Oncologyno. 1 (2024): 46-61

引用0浏览0WOS引用

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

Andrey Soares, Fernando Sabino Marques Monteiro,Karine Martins da Trindade, Adriano Gonçalves e Silva,Ana Paula Garcia Cardoso, André Deeke Sasse,André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andrade Mota, Bruno Santucci, Daniel da Motta Girardi,

Journal of Cancer Research and Clinical Oncology（2024）

引用0浏览0WOS引用

Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma

Ray Manneh Kopp, Fernando Galanternik,Fabio A Schutz, Fabio Kater,Allan Ramos-Esquivel, Silvia Neciosup, Nora Sobrevilla-Moreno, Laura Bernal Vaca, Linda Ibatá-Bernal, Susan Martínez-Rojas,Maria T Bourlon

JCO Global Oncologyno. 10 (2024): e2300244-e2300244

引用0浏览0WOS引用

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study